Edition:
United Kingdom

SCYNEXIS Inc (SCYX.OQ)

SCYX.OQ on NASDAQ Stock Exchange Global Market

1.16USD
25 Apr 2018
Change (% chg)

-- (--)
Prev Close
$1.16
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
58,443
52-wk High
$2.87
52-wk Low
$1.05

Chart for

About

SCYNEXIS, Inc. is engaged in the discovery, development and commercialization of anti-infectives. The Company is developing its lead product candidate, SCY-078, as an oral and intravenous (IV) drug for the treatment of several fungal infections, including serious invasive fungal infections. SCY-078 is a structurally distinct... (more)

Overall

Beta: 0.26
Market Cap(Mil.): $58.51
Shares Outstanding(Mil.): 46.84
Dividend: --
Yield (%): --

Financials

  SCYX.OQ Industry Sector
P/E (TTM): -- 29.67 32.21
EPS (TTM): -0.93 -- --
ROI: -54.61 13.44 13.05
ROE: -89.13 15.16 14.90

BRIEF-Caxton Corporation Reports 9.99 Percent Passive Stake In Scynexis Inc As Of March 6, 2018 - SEC Filing‍​

* CAXTON CORPORATION REPORTS 9.99 PERCENT PASSIVE STAKE IN SCYNEXIS INC AS OF MARCH 6, 2018 - SEC FILING‍​ Source text (http://bit.ly/2tII9WD) Further company coverage: (Reuters.Brief@thomsonreuters.com)

13 Mar 2018

BRIEF-SCYNEXIS Announces Pricing Of $30 Mln Public Offering Of Common Stock And Warrants

* SCYNEXIS ANNOUNCES PRICING OF $30.0 MILLION PUBLIC OFFERING OF COMMON STOCK AND WARRANTS

06 Mar 2018

BRIEF-Scynexis Inc Presents New In Vivo Data Highlighting The Potential Of Scy-078

* SCYNEXIS PRESENTS NEW IN VIVO DATA HIGHLIGHTING THE POTENTIAL OF SCY-078 USED IN COMBINATION FOR THE TREATMENT OF ASPERGILLUS INFECTIONS AT AAA 2018 Source text for Eikon: Further company coverage:

01 Feb 2018

BRIEF-Scynexis Provides Corporate And SCY-078 Pipeline Update

* SCYNEXIS INC - ‍INTENDS TO INITIATE A PHASE 1 STUDY IN HEALTHY VOLUNTEERS IN Q3 2018, PENDING FDA'S REVIEW FOR LIPOSOMAL IV FORMULATION OF SCY-078​

04 Jan 2018

BRIEF-Scynexis reports third quarter 2017 financial results

* Scynexis reports third quarter 2017 financial results and provides company update

07 Nov 2017

Earnings vs. Estimates